0000000000450331

AUTHOR

Romano N

showing 2 related works from this author

Isolation of HTLV III/LAV from drug addicts in Palermo.

1987

The new human retroviruses HTLV III/LAV, implicated as the causative agent of AIDS, have been isolated from peripheral blood lymphocytes of 5 of 13 drugs abusers with acquired immunodeficiency syndrome-related complex (ARC). In one patient the virus was also found in cell-free plasma. No HTLV III/LAV was detected in or isolated from 5 clinically healthy drug abusers. The lymphocytes were cultured with interleukin 2 and expressed either a transcriptase reverse activity or HTLV III/LAV antigens within 2-3 weeks of cultivation. The viruses were also transmitted into normal lymphocytes from cord blood of human newborns. At the present state of development, virological investigation, other than …

HTLIII/LAV PalermoAIDS-Related Complex/microbiologyMaleRiskAIDS-Related ComplexSubstance-Related DisordersHIVHumansFemaleLymphocytesisolation HTLIII/LAVSettore MED/42 - Igiene Generale E ApplicataSicilyMicrobiologica
researchProduct

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct